HonorStocks Biotech Gold Oil Mining China Asian MENU
Biotech Gold Oil Mining China Asian
Find Tomorrow's Winners Today

Stock technical analysis
Rating Flag Rating Flag Rating Flag Rating Flag Rating Flag
sell neutral buy
Actinium Pharmaceuticals, Inc. (ATNM)
0.4251  -0.0029  (-0.68%) 08-10 01:30
Open: 0.418 High: 0.43
Pre.close: 0.428 Low: 0.382
Volume: 32,895,993 Ave vol: 21,956,311
52w High: 0.649 52w Low: 0.157
MA(50): 0.441 MA(200): 0.284
EPS: -0.134 P/E Ratio: 0
Company profile
Exchange: AMEX
Sector: Healthcare
Industry: Biotechnology
Website: http://www.actiniumpharma.com
Market Cap (M): 168
Shares Out (M): 395
Actinium Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on developing and commercializing therapies for bone marrow transplant or adoptive cell therapies. Its lead product candidate is Iomab-B, which is in a pivotal Phase III clinical trial as an induction and conditioning agent in patients over the age of 55 with relapsed or refractory acute myeloid leukemia prior to receiving a bone marrow transplant, also known as a hematopoietic stem cell transplant. The company is also developing Actimab-A, its lead alpha-particle drug candidate that is in a Phase II trial for patients newly diagnosed with AML age 60 and over; and Actimab-M, a drug candidate, for the treatment of patients with penta refractory multiple myeloma in a Phase 1 clinical trial. Its Antibody Warhead Enabling technology platform is currently being utilized in a research collaboration with Astellas Pharma, Inc. The company was founded in 2000 and is based in New York, New York.
Technical analysis
Overall: Underperform
MA: Bullish MACD: Bearish
KDJ: Bearish RSI: Bearish
Target 1: 0.61 Target 2: 0.76
Resist 1: 0.52 Resist 2: 0.65
Support 1: 0.32 Support 2: 0.27
Company key metrics
Revenue per Share: 0
Net Income per Share: 0
Cash per Share: 0
Book Value per Share: 0
Price to Sales: 0
Price to Book Value: 0
Earnings Yield: 0
Dividend Yield: 0
Debt to Equity: 1.0676
Debt to Assets: 0.5163
Financial analysis
Price to Book Value: Outperform
Return on Assets: Underperform
Return on Equity: Underperform
Discounted cash flow: Outperform
Price to Earnings: Underperform
Debt to Equity: Outperform
Stock Charts
Headline news
Thu, 06 Aug 2020
Analyzing Future Direction of Actinium Pharmaceuticals, Inc. (ATNM): Next Earning Report on 08/07/2020 - The News Heater

Tue, 04 Aug 2020
Actinium Pharmaceuticals (ATNM) Stock Sinks As Market Gains: What You Should Know - Yahoo Finance

Mon, 03 Aug 2020
Actinium (ATNM) to Report Q2 Earnings: What's in the Cards? - Yahoo Finance

Wed, 29 Jul 2020
Actinium Pharmaceuticals Inc. (AMEX:ATNM) Finding Zero Support - The Oracle Dispatch

Mon, 27 Jul 2020
Is Actinium Pharmaceuticals Inc (ATNM) Stock a Great Value? - InvestorsObserver

Thu, 23 Jul 2020
Actinium Pharmaceuticals (ATNM) is a Great Momentum Stock: Should You Buy? - Yahoo Finance

HonorStocks, Find Tomorrow's Winners Today

©HonorStocks.com | U.S. stock markets, stock quotes and stock analysis. Data and information is provided for informational purposes only, is not intended for trading purposes and is not investment advice. Neither HonorStocks.com nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. Market data provided by: IEX and Financial Modeling Prep

Privacy Policy: Third parties, including Google, may be placing and reading cookies on your browsers, or other methods to collect information as a result of ad serving on this website. Google's use of advertising cookies enables it and its partners to serve ads to you based on your visit to this site and/or other sites on the Internet. You may opt out of personalized advertising by visiting Ads Settings. If you choose to use this website, you agree to the collection and use of information in relation to this policy. The information collected is used for providing and improving the ads Service. We will not use or share information with anyone, and we do not store any data from users.